Cargando…
Synergistic Anti-Tumor Activity by Targeting Multiple Signaling Pathways in Ovarian Cancer
SIMPLE SUMMARY: Ovarian cancer remains the most lethal gynecological cancer in women. There is a critical need to develop novel strategies that can be used to improve the survival of patients with advanced and recurrent ovarian cancer. Preclinical and early clinical studies with single-targeted agen...
Autores principales: | Wen, Wei, Han, Ernest S., Dellinger, Thanh H., Lu, Leander X., Wu, Jun, Jove, Richard, Yim, John H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564386/ https://www.ncbi.nlm.nih.gov/pubmed/32927828 http://dx.doi.org/10.3390/cancers12092586 |
Ejemplares similares
-
Ruxolitinib synergistically enhances the anti-tumor activity of paclitaxel in human ovarian cancer
por: Han, Ernest S., et al.
Publicado: (2018) -
Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer
por: Wen, Wei, et al.
Publicado: (2015) -
Increasing Antitumor Activity of JAK Inhibitor by Simultaneous Blocking Multiple Survival Signaling Pathways in Human Ovarian Cancer
por: Wen, Wei, et al.
Publicado: (2019) -
Pterostilbene Suppresses Ovarian Cancer Growth via Induction of Apoptosis and Blockade of Cell Cycle Progression Involving Inhibition of the STAT3 Pathway
por: Wen, Wei, et al.
Publicado: (2018) -
Prognostic Significance of B-Cells and pSTAT3 in Patients with Ovarian Cancer
por: Yang, Chunmei, et al.
Publicado: (2013)